Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease

Thrombosis and Haemostasis

Volumn 83, Issue 2, 2000, Pages 274-281

  Tout, Hélène ^a   Obert, Bernadette ^a   Houllier, Anne ^a   Fressinaud, Edith ^a   Rothschild, Chantal ^a   Meyer, Dominique ^a   Girma, Jean Pierre ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b Dept Environ Med Natl Inst Publ HIth   (Norway)

Author keywords

Alloantibddies; Binding; Type 3 vWD; vWF

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; BOTROCETIN; COLLAGEN TYPE 3; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN SUBCLASS; RECOMBINANT BLOOD CLOTTING FACTOR 8; RISTOCETIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BINDING AFFINITY; BINDING SITE; CASE REPORT; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHOOL CHILD; VON WILLEBRAND DISEASE;

EID: 0033950566     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613799     Document Type: Article

References (45)

1. Mancuso DJ, Tuley EA, Castillo R, de Bosch N, Mannucci PM, Sadler JE. Characterization of partial gene deletions in type III von Willebrand Disease with alloantihody inhibitors. Thromb Haemost 1994; 72: 180-5.
2. Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand Disease. J Clin Invest 1987; 79: 1459-65.
3. Ngo KY, Glotz T, Koziol JA, Lynch D, Gitscher J, Ranieri P, Ciavarella N, Ruggeri ZM, Zimmerman TS. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA 1988; 85: 2753-7.
4. Peake IR, Liddell MB, Moodie P, Standen G, Mancuso DJ, Tuley EA, Westfield LA, Sorace JM. Sadler JE, Verweij CL, Bloom AL. Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: Family studies that identify carriers of the condition and a compound heterozygous individual. Blood 1990; 75: 654-61.
5. Mannucci PM, Cattaneo M. Alloantibodies in congenital von Willebrand's disease. Res Clin Lab 1991; 21: 119-25.
6. Bahnak BR, Lavergne JM, Rothschild C, Meyer D. A stop codon in a patient with severe type III von Willebrand disease. Blood 1991; 78: 1148-9.
7. Eikenboom JCJ, Briët E, Reitsma PH, Ploos van Amstel HK. Severe type III von Willebrand's disease in the Dutch population is often associated with the absence of von Willebrand factor messenger RNA. Thromb Haemost 1991; 65: 1127.
8. Zhang ZP, Falk G, Blombäck M, Egberg N, Anvret M. Identification of a new nonsense mutation in the von Willebrand factor gene in patients with von Willebrand disease type III. Hum Mol Gen 1992; 1: 61-2.
9. Girma JP, Ribba AS, Meyer D. Structure-function relationship of the A1 domain of von Willebrand Factor. Thromb Haemost 1995; 74: 156-60.
10. Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Andersson LO, Meyer D. Localization of a Factor VIII binding domain on a 34 kilodalton fragment on the N-terminal portion of von Willebrand Factor. Blood 1987; 70: 1679-82.
11. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major Factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand Factor. J Biol Chem 1987; 262: 8443-6.
12. Hamilton KK, Fretto LJ, Grierson DS, McKee PA. Effects of plasmin on von Willebrand Factor multimers. Degradation in vitro and stimulation of release in vivo. J Clin Invest 1985; 76: 261-70.
13. Marti T, Rösselet SJ, Titani K, Walsh KA. Identification of disulfide bridges substructures within human von Willebrand factor. Biochemistry 1987; 26: 8099-109.
14. Girma JP, Chopek MW, Titani K, Davie EW. Limited proteolysis of human von Willebrand Factor by Staphylococcus aureus V-8 protease. Biochemistry 1986; 25: 3156-63.
15. Girma JP, Kalafatis M, Pietu G, Lavergne JM, Chopek MW, Edgington TS, Meyer D. Mapping of distinct von Willebrand factor domains interacting with platelet GPIb and GPIIb/IIIa and with collagen using monoclonal antibodies. Blood 1986; 67: 1356-66.
16. Andrews RK, Gorman JJ, Booth WJ, Corino GL, Castaldi PA, Berndt MC. Cross-linking of a monomeric 39/34 kDa dispase fragment of von Willebrand Factor (Leu 480/Val 481 - Gly 718) to the N-terminal region of the alpha chain of membrane glycoprotein Ib on the intact platelets with his (sulfosuccinimidyl) suberate. Biochemistry 1989; 28: 8326-36.
17. Fujimura Y, Titani K, Holland LZ, Robbers JR, Hostel P, Ruggeri ZM, Zimmerman TS. A heparin-binding domain of human von Willebrand factor. Charactcrization and localization of a tryptic fragment extending from ammoniated residue Val-449 and Lys-728. J Biol Chem 1987; 262: 1734-9.
18. Berndt MC, Ward CM, Booth WJ, Castaldi PA, Mazurov AV, Andrews R. Identification of aspartic acid-514 through glutamic acid-542 as a glycoprotein-Ib-IX complex receptor recognition sequence in von Willebrand Factor - Mechanism of modulation of von Willebrand Factor by ristocetin and botrocetin. Biochemistry 1992; 31: 11144-51.
19. Sugimoto M, Mohri H, Mcclintock RA, Ruggeri ZM. Identification of discontinuous von Willebrand Factor sequences involved in complex formation wilh botrocetin - A model for the regulation of von Willebrand Factor binding to platelet glycoprotein Ib. J Biol Chem 1991; 266: 18172-8.
20. Hamako J, Matsui T, Suzuki M, Ito M, Makita K, Fujimura Y, Ozeki Y, Titani K. Purification and characterization of bitiscetin, a novel von Willebrand Factor modulator protein from Bitis arietans snake venom. Biochem Biophys Res Commun 1996; 226: 273-9.
21. Obert B, Houllier A, Meyer D, Girma JP. Conformational changes in the A3 domain of von Willebrand Factor modulate the interaction of the A1 domain with platelet GP Ib. Blood 1999; 93: 1959-68.
22. Cruz MA, Yuan HB, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand factor (vWF) with collagen - Localization of the primary collagen-binding site by analysis of recombinant vWF A domain polypeptides. J Biol Chem 1995; 270: 10822-7.
23. Lankhof H, Vanhoeij M, Schiphorst ME, Bracke M, Wu YP, Ijsseldijk MJ, Vink T, Degroot PG, Sixma JJ. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost 1996; 75: 950-8.
24. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie G, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand Factor binding to platelets. Proc Natl Acad Sci USA 1985; 82: 8057-61.
25. Mannucci PM, Tamaro G, Narchi G, Candotti G, Federici A, Altieri D, Tedesco F. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol 1987; 39: 467-70.
26. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease : Role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125: 348-55.
27. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand Disease wilh defective binding to Factor VIII. Blood 1989; 74: 1591-9.
28. Ruggeri ZM, Ciavarella N, Mannucci PM, Molinari A, Dammacco F, Lavergne JM, Meyer D. Familial incidence of precipitating antibodies in von Willebrand's Disease : a study of four cases. J Lab Clin Med 1979; 94: 60-75.
29. Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde : a new reagent for assay of von Willebrand Factor and platelet aggregating Factor. J Lab Clin Med 1975; 85: 318-28.
30. Steinbuch M, Audran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys 1969; 134: 279-84.
31. Laemmli UK. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 1970; 227: 680-5.
32. Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand Factor for binding to platelet membrane glycoprotein Ib. Thromb Haemost 1990; 64: 326-32.
33. Christophe O, Obert B, Meyer D, Girma JP. The binding domain of von Willebrand Factor to sulfatides is distinct from those interacting with glycoprotein Ib, heparin, and collagen and resides between amino acid residues Leu 512 and Lys 673. Blood 1991; 78: 2310-7.
34. Christophe O, Ribba AS, Baruch D, Obert B, Rouault C, Niinomi K, Pietu G, Meyer D, Girma JP. Influence of mutations and size of multimers in type II von Willebrand Disease upon the function of von Willebrand Factor. Blood 1994; 83: 3553-61.
35. Meyer D, Zimmerman TS, Obert B, Edgington TS. Hybridoma antibodies to human von Willebrand Factor. I. Characterization of seven clones. Brit J Haematol 1984; 57: 597-608.
36. Christophe O, Rouault C, Obert B, Pietu G, Meyer D, Girma JP. A monoclonal antibody (B724) to von Willebrand Factor recognizing an epitope within the A1 disulphide loop (Cys 509-Cys 695) discriminates between type 2A and type 2B von Willebrand Disease. Brit J Haematol 1995; 90: 195-203.
37. Nokes TJC, Mahmoud NA, Savidge GF, Goodall AH, Meyer D, Edgington TS, Hardisty RM. von Willebrand Factor has more than one binding site for platelets. Thromb Res 1984; 34: 361-6.
38. Pietu G, Ribba AS, Cherel G, Siguret V, Obert B, Rouault C, Ginsburg D, Meyer D. Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand Factor by using recomhinant cDNA libraries. Thromb Haemost 1994; 71: 788-92.
39. Fracker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1, 3, 4, 6-tetrachloro-3a, 6a-diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-57.
40. Kalafatis M, Takahashi Y, Girma JP, Meyer D. Localization of a collagen-interactive domain of human von Willebrand Factor between amino acid residues Gly 911 and Glu 1,365. Blood 1987; 70: 1577-83.
41. Steiner B, Cousot D. Trzeciak A, Gillessen D, Hadvary P. Ca(2+)-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb/IIIa complex. J Biol Chem 1989; 264: 13102-8.
42. Lopez-Fernandez MF, Martin R, Lopez-Berges C, Ramos F, de Bosch N, Battle J. Further specificity characterization of von Willebrand Factor inhibitors developed in two patients with severe von Willebrand Disease. Blood 1988; 72: 116-20.
43. Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchkine MD, Mowbray JF. Precipitating antibodies to factor VIII/von Willebrand Factor in von Willebrand Disease: effects on replacement therapy. Blood 1981; 57: 25-31.
44. Mohri H, Yamazaki E, Suzuki Z, Takano T, Yokota S, Okubo T. Autoantibody selectively inhibits binding of von Willebrand Factor to glycoprotein Ib. Recognition site is located in the A1 loop of von Willebrand Factor. Thromb Haemost 1997; 77: 760-6.
45. Meyer D, Fressinaud E, Gaucher C, Lavergne JM, Hilbert L, Ribba AS, Jorieux S, Mazurier C, the INSERM Network on Molecular Abnormalities in von Willebrand Disease. Gene defects in 150 unrelated trench cases with type 2 von Willebrand Disease: from the patient to the gene. Thromb Haemost 1997; 78: 451-6.